Application of immune adjuvant combined with PD-1 antibody in the treatment of pancreatic cancer

By injecting QS-21 and Poly I:C as immune adjuvant and PD-1 antibody into pancreatic cancer tumors, the anti-tumor immune response was activated, and the problem of the microenvironment of pancreatic cancer tumor hindering immune cell infiltration was solved, which significantly improved the Treatment effects and immune memory reduce drug resistance.

CN117982638BActive Publication Date: 2024-11-01SHANGHAI AYK BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410159281.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-04
Publication Date
2024-11-01
Estimated Expiration
2044-02-04

AI Technical Summary

Technical Problem

The dense fibrous tissue of the tumor microenvironment of pancreatic cancer hinders the entry of anti-tumor drugs and infiltration of immune cells, resulting in poor immunotherapy effects and low monotherapy treatment of PD-1/PD-L1 inhibitors.

Method used

QS-21 and polymyosylitol Poly I:C are used as immune adjuvant and PD-1 antibody in combination. Immune adjuvant is injected into pancreatic cancer tumors through tumor in situ vaccine technology to activate anti-tumor immune response and change tumors Microenvironment, enhancing T cell infiltration and immune memory.

Benefits of technology

It significantly improves the sensitivity of pancreatic cancer to PD-1 antibody drugs, reduces or reverses drug resistance, enhances systemic anti-tumor immune effects, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117982638B_ABST
    Figure CN117982638B_ABST
Patent Text Reader

Abstract

The present invention discloses the application of an immune adjuvant combined with a PD-1 antibody drug in the treatment of pancreatic cancer, and relates to the field of biomedicine. The present invention uses an immune adjuvant containing QS-21 and polyinosinic acid (Poly I:C) as an in situ tumor vaccine alone, which can effectively treat or improve pancreatic cancer. When used in combination with a PD-1 antibody drug, it can reduce or reverse the drug resistance of pancreatic cancer patients to PD-1 antibody drugs, and can also change the tumor microenvironment of pancreatic cancer patients, induce specific anti-tumor immune memory and systemic anti-tumor immune effects, so that the anti-tumor effects of immune adjuvants and PD-1 antibody drugs are significantly improved, providing a new approach for the effective treatment of pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular, to the use of an immune adjuvant combined with a PD-1 antibody drug in the treatment of pancreatic cancer. Background Art

[0002] In situ vaccination (ISV) is a form of immunotherapy that uses the tumor as its own vaccine. After a small amount of immunomodulatory agents (adjuvants) are injected directly into the tumor through intratumoral injection, high concentrations of immune stimulatory products can be obtained in situ to achieve therapeutic effects. The advantage of in situ tumor vaccines is that local delivery allows a variety of combination therapies while preventing significant systemic exposure and off-target toxicity. Although the dominant epitope of a particular cancer is not determined, one can trigger an immune response against tumor neoantigens or tumor-associated antigens without characterizing them. Due to the circulation of appropriately activated anti-tumor immune cells, this immune stimulation can induce strong tumor immune priming locally while producing systemic (distant) tumor responses. While addressing many of the current limitations in the development of cancer immunotherapy, intratumoral immunotherapy also provides a unique opportunity to better understand the dynamics of cancer immunity by allowing serial and multifocal biopsies at each tumor injection.

[0003] Tumor in situ vaccines are designed to stimulate the first three steps of the anticancer immunity cycle: cancer antigen release and presentation, immune cell priming, and immune cell activation. Once immune cells are activated, they still need to complete the remaining steps: peripheral mobilization, infiltration into cancer sites, recognition of cancer cells, and stimulation of cytotoxicity against cancer cells. Therefore, resistance mechanisms of anticancer immunity, especially those in the TME, still reduce the efficiency of cancer vaccines, and methods to enhance cancer vaccines are currently being explored.

[0004] Immunotherapies such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially metastatic cancer, with some patients previously considered incurable achieving long-term remission and survival. However, although immunotherapy can produce durable responses, the response rate of ICI monotherapy for solid tumors is usually only about 20%, and many patients eventually develop secondary resistance. Once immune cells enter the tumor immune microenvironment (TME), many mechanisms are generated to induce resistance to anti-tumor immunity, including cancer cell intrinsic factors, immunosuppressive cells, and immunosuppressive environment.

[0005] The unique tumor microenvironment of pancreatic cancer is one of the important reasons why its malignancy is far higher than that of other tumors. It is also one of the main reasons why pancreatic cancer patients are insensitive to chemoradiotherapy and immunotherapy and have poor prognosis. There are a large number of dense matrix components in the tumor microenvironment of pancreatic cancer, which, on the one hand, provides favorable conditions for the growth of pancreatic cancer cells. On the other hand, the dense fibrous tissue compresses the blood vessels in the pancreatic cancer tissue, making it impossible for anti-tumor drugs to enter the cancer tissue and exert their effects. At the same time, the dense fibrous tissue prevents the infiltration of immune effector cells such as CD8+T cells and NK cells in the tumor tissue, allowing the tumor tissue to escape the surveillance of the immune system.

[0006] Studies have found that about 30% of pancreatic cancer patients have positive expression of PD-L1. However, clinical data show that monotherapy with PD-1 / PD-L1 inhibitors is not effective in treating pancreatic cancer patients.

[0007] In view of this, the present invention is proposed. Summary of the invention

[0008] The purpose of the present invention is to provide an application of an immune adjuvant combined with a PD-1 antibody drug in the treatment of pancreatic cancer.

[0009] The present invention is achieved in that:

[0010] In a first aspect, an embodiment of the present invention provides an application of a composition in the preparation of a product for treating or adjuvanting pancreatic cancer, wherein the active ingredients of the composition include: an immune adjuvant and a PD-1 antibody drug; the active ingredients of the immune adjuvant include QS-21 and polyinosinic acid (Poly I:C).

[0011] In a second aspect, an embodiment of the present invention provides a pharmaceutical composition, which includes: the composition described in the above embodiment.

[0012] In a third aspect, an embodiment of the present invention provides a kit, which includes: the composition described in the aforementioned embodiment.

[0013] In a fourth aspect, embodiments of the present invention provide use of the immune adjuvant described in the aforementioned embodiments in the preparation of a product for treating or assisting in the treatment of pancreatic cancer.

[0014] The present invention has the following beneficial effects:

[0015] The present invention finds that an immune adjuvant containing QS-21 and polyinosinic acid (Poly I:C) as active ingredients can be used alone as an in situ tumor vaccine to effectively treat or improve pancreatic cancer. When used in combination with a PD-1 antibody drug, it can reduce or reverse the drug resistance of pancreatic cancer patients to PD-1 antibody drugs, and can also change the tumor microenvironment of pancreatic cancer patients, induce specific anti-tumor immune memory and systemic anti-tumor immune effects, so that the anti-tumor effects of the immune adjuvant and PD-1 antibody drug are significantly improved, providing a new approach for the effective treatment of pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0017] Figure 1 To compare the anti-tumor effects of three different adjuvants;

[0018] Figure 2 Schematic diagram of the dosing process of AYK103 combined with PD-1 in the treatment of PD-1-resistant pancreatic cancer in mice;

[0019] Figure 3 This is the tumor growth curve of AYK103 combined with PD-1 in the treatment of pancreatic cancer in PD-1-resistant mice;

[0020] Figure 4 This is the anatomy of tumor tissue of AYK103 combined with PD-1 in the treatment of pancreatic cancer in PD-1-resistant mice;

[0021] Figure 5 The number of CD8+T cells in the tumor immune microenvironment of pancreatic cancer in PD-1-resistant mice treated with AYK103 combined with PD-1;

[0022] Figure 6 The number of CD4+T cells in the tumor immune microenvironment of pancreatic cancer in PD-1-resistant mice treated with AYK103 combined with PD-1;

[0023] Figure 7 The number of CD8+CD69+T cells in the tumor immune microenvironment of pancreatic cancer in PD-1-resistant mice treated with AYK103 combined with PD-1. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0025] According to the different sources of tumor antigen expression, therapeutic tumor vaccines are divided into four categories, namely cell vaccines, protein / synthetic peptide vaccines, nucleic acid vaccines and viral vector vaccines. However, each of these four types of tumor vaccines has its own limitations. Cell vaccines have weak immunogenicity and secrete multiple inhibitory factors, which will lead to poor vaccine effects and kill healthy cells in the body; nucleic acid vaccines have weak delivery efficiency and poor stability; viral vector vaccines cannot be repeatedly vaccinated, otherwise the immune response produced by the body will attack the viral vector vaccine that enters our body again.

[0026] In order to make up for the defects of the above-mentioned vaccines, an embodiment of the present invention provides a tumor in situ vaccine. The vaccine does not involve antigens, and the new immune adjuvant system AYK103 is injected into the tumor to form an in situ vaccine in situ using the tumor tissue's own antigens in situ. Compared with nucleic acid and viral vector vaccines, it avoids the problem of low tumor delivery efficiency and has higher stability and safety. The adjuvant system has the characteristics of low cost, short cycle, low drug resistance, and can improve immunogenicity through multiple injections. Compared with traditional subunit vaccines and gene vaccines, the tumor in situ vaccine (immune adjuvant) provided by the present invention does not contain antigens and haptens and has higher safety. Compared with cell therapies such as DC vaccines, the immune adjuvant provided by the present invention has low price, short cycle, low toxicity, good broad spectrum, and is easier to use in combination with other therapies, providing more options for the development of new clinical tumor clinical treatment strategies.

[0027] Tumor in situ vaccines can activate antigen presenting cells in the immune microenvironment of tumor tissue, so that antigen presenting cells present tumor neoantigens and tumor-specific antigens in tumor tissue to the draining lymph nodes, generating specific T cell immunity. Through research and exploration of pancreatic cancer, the inventors of this application have discovered and verified that the use of immune adjuvants of specific active ingredients (QS-21 and Poly I:C) as tumor in situ vaccines in combination with PD-1 antibody drugs can effectively change the pancreatic cancer tumor microenvironment, increase the proportion of T cells in the pancreatic cancer tumor microenvironment, improve the poor effect of PD-1 antibody drug treatment, and at the same time, it also has the effect of inducing specific anti-tumor immune memory and systemic anti-tumor immune effects.

[0028] The immune adjuvant provided by the present invention and the combined treatment of the immune adjuvant and the PD-1 antibody drug can be used to effectively treat pancreatic cancer patients (stage I, stage II, stage III, stage IV), pancreatic cancer patients who are resistant to PD-1 antibody drugs, and patients with advanced (stage III, IV) pancreatic cancer who have failed first-line treatment.

[0029] Specific technical solutions

[0030] On the one hand, an embodiment of the present invention provides an application of a composition in the preparation of a product for treating or adjuvanting pancreatic cancer, wherein the active ingredients of the composition include: an immune adjuvant and a PD-1 antibody drug; the active ingredients of the immune adjuvant include QS-21 and polyinosinic acid Poly I:C.

[0031] Polyinosinic-polycytidylic acid (Poly I:C) is a toll-like receptor 3 (TLR3) agonist and a synthetic double-stranded RNA (dsRNA). CAS No.: 42524-50-0.

[0032] QS-21, CAS No. 141256-04-4, molecular formula: C 92 H 148 O 46 , molecular weight: 1990.14.

[0033] In some embodiments, the administration method of the tumor in situ vaccine is intratumoral injection of pancreatic cancer, which utilizes the tumor's own antigen combined with immune adjuvant (AYK103) to form a tumor in situ vaccine in the tumor site, activate the anti-tumor immune response in the tumor tissue, and enhance immune memory.

[0034] In some embodiments, the PD-1 antibody drug is administered by intraperitoneal injection.

[0035] In some embodiments, in the immune adjuvant, the final concentration of QS-21 is 50-300 μg / mL. The final concentration can be any one of 50, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300 μg / mL or a range between any two thereof.

[0036] In some embodiments, in the immune adjuvant, the final concentration of polyinosinic acid Poly I:C is 400-3000 μg / mL. The final concentration can be any one of 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000 μg / mL or a range between any two thereof.

[0037] In some embodiments, the immune adjuvant further comprises: a liposome carrier;

[0038] In some embodiments, in the immune adjuvant, the mass ratio of QS-21, Poly I:C and DOPC is 1:6-10:15-25, specifically it can be any one of 1:6:16, 1:6:18, 1:6:20, 1:6:22, 1:6:24, 1:8:16, 1:8:18, 1:8:20, 1:8:22, 1:8:24, 1:10:16, 1:10:18, 1:10:20, 1:10:22, 1:10:24, or the range between any two of them.

[0039] In some embodiments, the liposome carrier comprises: any one or more of a cationic liposome and a neutral liposome.

[0040] In some embodiments, the cationic liposomes include any one or more of DOTAP, DOTMA, and DC-Chol.

[0041] In some embodiments, the neutral liposomes include any one or more of DOPC, DSPC, and DPPC.

[0042] In some embodiments, the mass ratio of the cationic liposome to the neutral liposome is 1:8-12, and can be any one of 1:8, 1:9, 1:10, 1:11, 1:12, or a range between any two of them.

[0043] In some embodiments, the particle size of the cationic liposome is 100-300 nm, and the particle size can be any one of 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300 nm or a range between any two thereof.

[0044] In some embodiments, the method for preparing the cationic liposome comprises:

[0045] Mixing 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol in a mass ratio of 1:8 to 12:3 to 4 to obtain a first mixture;

[0046] The first mixture is used as a raw material, and cationic liposomes are prepared by using any one of an ethanol injection method, a thin film dispersion method, an ultrasonic dispersion method, and a reverse evaporation method.

[0047] In some embodiments, the mixing mass ratio of 1,2-dioleoyl-3-trimethylammonium chloride propane (DOTAP), dioleoylphosphatidylcholine (DOPC) and cholesterol can be any one of 1:8:3, 1:8:4, 1:9:3, 1:9:4, 1:10:3, 1:10:4, 1:11:3, 1:11:4, 1:12:3, 1:12:4, or a range between any two of them.

[0048] In some embodiments, the particle size of the neutral liposome is 100-300 nm, and the particle size can be any one of 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300 nm or a range between any two thereof.

[0049] In some embodiments, the method for preparing the neutral liposome comprises:

[0050] Mixing dioleoylphosphatidylcholine (DOPC) and cholesterol in a mass ratio of 3 to 5:1 to obtain a second mixture;

[0051] The second mixture is used as a raw material, and neutral liposomes are prepared by any one of an ethanol injection method, a thin film dispersion method, an ultrasonic dispersion method and a reverse evaporation method.

[0052] In some embodiments, the mixing mass ratio of dioleoylphosphatidylcholine and cholesterol can be any one of 3:1, 3.5:1, 4:1, 4.5:1, 5:1 or a range between any two of them.

[0053] In some embodiments, the product is any one of a drug, a reagent, and a kit.

[0054] The technical solution of the present invention has no special restrictions on PD-1 antibody drugs, and existing disclosed PD-1 antibody drugs can be selected. In some embodiments, the PD-1 antibody drugs include: any one or more combinations of pembrolizumab, nivolumab, atezolizumab, durvalumab, sintilimab, toripalimab, tislelizumab, carrelizumab, slulizumab, putalimab, penpulimab, envolimab, sepalimab and cardunili.

[0055] In some embodiments, the treating or adjuvant treating pancreatic cancer comprises treating or adjuvant treating patients with stage I, stage II, stage III, or stage IV pancreatic cancer.

[0056] In some embodiments, the treating or adjuvant treating pancreatic cancer includes treating or adjuvant treating pancreatic cancer patients who are resistant or intolerant to PD-1 antibody drugs.

[0057] In some embodiments, the treating or adjuvant treating pancreatic cancer includes treating or adjuvant treating patients with advanced pancreatic cancer who have failed first-line treatment.

[0058] On the other hand, an embodiment of the present invention provides a pharmaceutical composition, which includes: the composition described in any of the aforementioned embodiments.

[0059] "Drug" and "pharmaceutical composition" can be equivalently substituted. The pharmaceutical composition includes not only the active ingredient of the present invention, but also a pharmaceutically acceptable carrier. The carrier includes, but is not limited to: diluents, buffers, suspensions, emulsions, granules, encapsulation agents, excipients, fillers, adhesives, sprays, transdermal absorbents, wetting agents, disintegrants, absorption accelerators, surfactants, colorants, flavoring agents and adsorption carriers, etc.

[0060] On the other hand, an embodiment of the present invention provides a kit, comprising: the composition described in any of the aforementioned embodiments.

[0061] In addition, an embodiment of the present invention also provides use of the immune adjuvant as described in any of the above embodiments in the preparation of a product for treating or assisting in the treatment of pancreatic cancer.

[0062] "Treatment" as used herein includes preventing or alleviating a condition, reducing the rate at which a condition develops or progresses, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or terminating symptoms associated with a condition, producing complete or partial reversal of a condition, curing a condition, or a combination of the above.

[0063] For cancer, "treatment" can refer to inhibiting or slowing the growth, reproduction, or metastasis of tumors or malignant cells, or some combination of the above. For tumors, "treatment" includes eliminating all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of the tumor, or some combination of the above.

[0064] The preparation of therapeutic drugs or pharmaceutical compositions and their subsequent use (administration) are within the capabilities of those skilled in the art. Administration depends on the severity and responsiveness of the disease state to be treated, and the period of treatment lasts for several days to several months, or until a cure is achieved or the alleviation of the disease state is achieved. The best dosing schedule can be calculated from the measurement of drug accumulation in the patient. One of ordinary skill in the art can easily determine the optimal dose, method of administration, and repetition rate. The optimal dose can vary according to the relative efficacy of the active ingredient, and can usually be estimated based on an effective EC50 in an effective in vitro and in vivo animal model.

[0065] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0066] The experimental animal use license number is SYXK(Su)2018-0019.

[0067] Example 1: AYK103 immune adjuvant (tumor in situ vaccine) and its preparation.

[0068] An immune adjuvant AYK103 comprises the following three components: QS-21, Poly I:C and liposome carrier.

[0069] (1) QS-21, final concentration in immune adjuvant is 100 μg / ml;

[0070] (2) Poly I:C, final concentration in immune adjuvant is 800 μg / ml;

[0071] (3) Liposome carrier: The liposome carrier is a cationic liposome preparation.

[0072] The preparation method of the immune adjuvant AYK103 is:

[0073] (1) Preparation of cationic liposomes:

[0074] 1,2-dioleoyl-3-trimethylammonium chloride propane (DOTAP), dioleoylphosphatidylcholine (DOPC) and cholesterol are prepared in a mass ratio of 1:10:3; after the three lipid components are evenly dispersed, the cationic liposomes are prepared using an ethanol injection method (in other embodiments, a thin film dispersion method, an ultrasonic dispersion method, or a reverse evaporation method can be used); the preparation steps of the ethanol injection method are: after ultrafiltration, extrusion molding is performed using extrusion membranes with pore sizes of 200 nm and 100 nm in sequence, and finally filtration and sterilization are performed through a sterile filter.

[0075] (2) QS-21, Poly I:C, and DOPC were mixed in a mass ratio of 1:8:20 and stirred evenly to prepare the immune adjuvant AYK103.

[0076] Example 2: Comparison of the effects of different immune adjuvants.

[0077] Three experimental groups were set up to prepare immune adjuvants AYK101, AYK102 and AYK103 respectively. AYK103 was AYK103 described in Example 1. AYK101 and AYK102 were roughly the same as AYK103 in Example 1, with the following differences:

[0078] AYK101 replaced Poly I:C with MPLA, and the final concentration of MPLA was 200 μg / mL;

[0079] AYK102 replaced QS-21 with MPLA, and the final concentration of MPLA was 200 μg / mL.

[0080] Experimental methods

[0081] Construction of B16-OVA cell line melanoma tumor model: Mouse melanoma B16-OVA cell line. Culture conditions: RPMI 1640 medium + 10% (volume fraction) FBS + 1% (volume fraction) double antibody. The mouse melanoma B16-OVA cell line was centrifuged at 1000r / min for 5 minutes. The cell survival rate was detected by 0.4% (volume fraction) trypan blue exclusion method (survival rate>90%), and the cells were washed 3 times with PBS and centrifuged at 1000r / min for 5 minutes. PBS was added to adjust the cell concentration to 5×10 6 100 μl of cell suspension was inoculated into the axilla of 20 female mice. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 5th day after tumor inoculation.

[0082] On the 5th day after tumor implantation, the subcutaneous tumor volume of female C57BL / 6J mice was measured, and the mice were randomly divided into 4 experimental groups according to the tumor volume, as follows: liposome control group (blank liposome negative control group without drug encapsulation, 100 μL / mouse / time), AYK101 (100 μL / mouse / time), AYK102 (100 μL / mouse / time), AYK103 (100 μL / mouse / time). There were 10 mice in each group, all of which were female. The first administration was performed on the day after grouping (9th day after tumor implantation), the second intratumoral injection was performed on the 12th day after tumor implantation, and the last intratumoral injection was performed on the 15th day after tumor implantation. The general conditions of the animals, such as body weight and diet, were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.

[0083] Experimental Results

[0084] Results reference Figure 1 It can be seen that among the three adjuvants AYK101, AYK102, and AYK103, AYK103 (Poly(I:C)+QS21) has the best effect in inhibiting tumor growth, with a tumor inhibition rate of about 96%.

[0085] Example 3: Construction of FC1242 cell line pancreatic cancer model.

[0086] The cell line is the mouse pancreatic cancer FC1242 cell line. Culture conditions: RPMI 1640 medium + 10% (volume fraction) FBS + 1% (volume fraction) double antibody. Animal species and strain: C57BL / 6J. Grade: SPF grade. Animal age: 6-8 weeks old. Feeding method: free intake. Adaptation period labeling: Cage cards and toe clipping are used as animal identification marks during environmental adaptation. The experimental animals are numbered according to the experimental animal numbering method of this institution, and the animal number information is marked on the cage card. During the environmental adaptation period, white cage cards are uniformly used, and the experimental number, animal strain, cage number, number of animals, entry time, remarks, etc. are indicated. Numbering after grouping: Cage cards and toes are used as animal identification marks.

[0087] Mouse pancreatic cancer FC1242 cell line was centrifuged at 1000r / min for 5 minutes. The cell survival rate was detected by 0.4% (volume fraction) trypan blue exclusion method (survival rate>90%), and the cells were washed 3 times with PBS and centrifuged at 1000r / min for 5 minutes. PBS was added to adjust the cell concentration, and 100μl of cell suspension was inoculated subcutaneously into 20 female mice, with 5×10 cells per mouse. 5 The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 4th day after the mice were implanted with tumors.

[0088] Example 4: AYK103 combined with PD-1 in the treatment of pancreatic cancer in PD-1-resistant mice.

[0089] Experimental methods

[0090] Grouping and Dosage Scheme: On the 4th day after tumor implantation, the subcutaneous tumor volume of female C57BL / 6J mice (FC1242 cell line pancreatic cancer model prepared in Example 3) was measured and randomly divided into 4 experimental groups according to the tumor volume, as follows:

[0091] Group 1 (Vehicle+IgG): blank liposomes (Vehicle, 100 μL / mouse / time) + immunoglobulin IgG (IgG from BioXCell, 100 μg / mouse / time);

[0092] Group 2 (Vehicle+anti-PD-1mAb): Vehicle (100 μL / vehicle / time) + anti-PD-1mAb (PD-1 antibody from BioXCell, 100 μg / vehicle / time);

[0093] Group 3 (AYK103): AYK103 group (100 μL / mouse / time);

[0094] Group 4 (anti-PD-1mAb+AYK103): anti-PD-1mAb (100μg / mouse / time) + AYK103 group (100μL / mouse / time).

[0095] There were 10 female mice in each group. The first intratumoral administration of AYK103 was performed on the day after grouping (5th day after tumor implantation), and the PD-1 monoclonal antibody was intraperitoneally administered on the second day (6th day after tumor implantation). The second intratumoral administration of AYK103 was performed on the 7th day after tumor implantation (same as Example 1), and the second intraperitoneal administration of PD-1 monoclonal antibody was performed on the second day. The third intratumoral administration of AYK103 was performed on the 10th day after tumor implantation, and the third intraperitoneal administration of PD-1 monoclonal antibody was performed on the second day. Observe the general conditions of the animals, such as body weight and diet, monitor the changes in mouse body weight every day, and detect changes in tumor size every two days. After the last administration, continue to observe for 7 days. For details on the dosage volume, route and frequency, see Figure 2 .

[0096] Tumor volume measurement: Drug administration began on the 4th day after tumor implantation, and the animal weight was monitored every day. The tumor volume was measured every three days using the tumor diameter measurement method to dynamically observe the anti-tumor activity of the test drug. The long and short diameters of the tumor were measured with a vernier caliper to calculate the tumor volume, tumor volume = 1 / 2 × long diameter × short diameter 2 .

[0097] Experimental Results

[0098] The results are as follows Figure 3 , 4 As shown: It reflects the growth of subcutaneous pancreatic cancer tumors in mice injected with Vehicle+IgG, Vehicle+PD-1 monoclonal antibody, AYK103+IgG, and combined injection of AYK103+PD-1 monoclonal antibody. Compared with the injection of Vehicle+IgG, the tumor growth in the AYK103+IgG injection group was significantly inhibited, indicating that AYK103 has the effect of treating pancreatic cancer in mice. However, the injection of Vehicle+PD-1 monoclonal antibody has almost no effect on the growth of pancreatic cancer in mice. For the combined injection of AYK103+PD-1 monoclonal antibody group, the growth of pancreatic cancer in mice was significantly inhibited, and the effect was better than that of the AYK103+IgG injection group, indicating that the combined use of AYK103 and PD-1 monoclonal antibody can produce a combined synergistic effect.

[0099] Example 5: AYK103 combined with PD-1 changes the tumor immune microenvironment in pancreatic cancer in mice.

[0100] Experimental methods

[0101] Tissue processing methods:

[0102] 1. Tumor tissue sampling: The mice constructed in Example 4 were killed by cervical dislocation, and the hair, skin and tissues of the mice were carefully parted with surgical scissors and elbow forceps to gently free the intact subcutaneous pancreatic cancer tumor. After weighing, recording and taking pictures, 0.1-0.5 g of each tumor tissue was retained and placed in pre-cooled 1× PBS;

[0103] 2. Preparation of single cell fluid of tumor tissue: prepare clean 5mL EP tubes according to the group number, cut the above tumor tissue into 5mm tissue blocks in the tube, use the prepared tissue digestion solution [RPMI-1640 culture medium, 0.5mg / ml collagenase D, 0.1mg / ml DNase I], resuspend the tumor tissue in a volume of 4mL digestion solution / sample, and transfer it to the gentle MACS C tube, run program 37C_Multi_F, after the program ends, remove the C tube from the gentle MACS tissue processor; rinse the filter with RPMI-1640, filter the grinding solution with a 70μm filter membrane, collect the cell suspension in a 10mL EP tube, centrifuge (400g, 5min, room temperature), discard the supernatant, prepare 1× red blood cell lysis buffer with pure water, resuspend the cell pellet in a volume of 2mL 1× red blood cell lysis buffer / sample, let it stand at room temperature for 5min, and add 5ml The lysis was terminated with 1× PBS, and the supernatant was discarded after centrifugation (400 g, 5 min, room temperature);

[0104] Flow staining method:

[0105] Live / Dead staining: resuspend the cell pellet in 100 μL of Live / Dead diluent (Near IR diluted with 1×PBS at a ratio of 1:500) per sample, incubate at 4°C in the dark for 30 min, terminate staining with 1 mL of 1×PBS, take a small amount of cell suspension from each sample for use as a Live / Dead single positive tube, centrifuge (400 g, 5 min, room temperature) and discard the supernatant.

[0106] Flow cytometry antibody staining: Use the prepared mixed staining solution (PE / Cy7-CD3, FITC-CD4, BV510-CD8, PE-CD25, BV421-CD69, APC-PD-1 at a ratio of 1:800, diluted with 1×PBS), resuspend the above cell pellet in a volume of 100μL mixed staining solution / sample, incubate at 4℃ in the dark for 30min, terminate staining with 1mL 1×PBS, centrifuge (400g, 5min, room temperature) and discard the supernatant. Each antibody single positive tube is stained with 0.2μL / tube of Beads for later use, and the staining method is the same as above.

[0107] Sample loading: Flow cytometer detection, first blank control tube and single positive tube for voltage definition, after the voltage is fixed, record the cell count of each group of samples, and use the sampled tumor tissue mass for cells / gtumor unit conversion.

[0108] Experimental Results

[0109] Results Figure 5 , Figure 6 and Figure 7 .

[0110] Depend on Figure 5 It can be seen that the CD8+T cells in the tumor tissue of the AYK103(Poly(I:C) / QS21)+PD-1 monoclonal antibody injection group were significantly higher than those in the blank liposome control (Vehicle)+IgG group, the blank liposome control (Vehicle)+PD-1 monoclonal antibody, and the AYK103(Poly(I:C) / QS21)+IgG group, which indicates that the combination of AYK103 and PD-1 monoclonal antibody can help CD8+T cells infiltrate into the tumor.

[0111] Depend on Figure 6 It can be seen that the CD4+T cells in the tumor tissue of the AYK103(Poly(I:C) / QS21)+PD-1 monoclonal antibody injection group were significantly higher than those in the blank liposome control (Vehicle)+IgG group, the blank liposome control (Vehicle)+PD-1 monoclonal antibody, and the AYK103(Poly(I:C) / QS21)+IgG group. This indicates that the combination of AYK103 and PD-1 monoclonal antibody can help CD4+T cells infiltrate into the tumor and assist CD8+T cells in functioning.

[0112] After CD8 T cells are activated, the expression of CD69 will be upregulated, so CD8+CD69+T cells are activated CD8 T cells. Figure 7 It can be seen that the CD8+CD69+T cells in the tumor tissue of the AYK103(Poly(I:C) / QS21)+PD-1 monoclonal antibody injection group were significantly higher than those in the blank liposome control (Vehicle)+IgG group, the blank liposome control (Vehicle)+PD-1 monoclonal antibody, and the AYK103(Poly(I:C) / QS21)+IgG group. This indicates that the combination of AYK103 and PD-1 monoclonal antibody can increase the number of activated CD8 T cells in tumor tissue, thereby better exerting the effect of killing tumors.

[0113] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of the composition in preparing a product for treating or assisting in treating pancreatic cancer, characterized in that: The active ingredients of the composition include: an immune adjuvant and a PD-1 antibody drug; the immune adjuvant is composed of QS-21, polyinosinic acid Poly I:C and a liposome carrier; In the immune adjuvant, the final concentration of QS-21 is 50-300 μg / mL, and the final concentration of polyinosinic acid Poly I:C is 400-3000 μg / mL; The liposome carrier comprises: cationic liposome; The preparation method of the immune adjuvant comprises: Mixing 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol in a mass ratio of 1:8-12:3-4 to obtain a first mixture; Using the first mixture as a raw material, preparing cationic liposomes by any one of an ethanol injection method, a thin film dispersion method, an ultrasonic dispersion method, and a reverse evaporation method; QS-21, Poly I:C, and liposome carrier are mixed in a mass ratio of 1:8-10:15-25 and stirred evenly to obtain the immune adjuvant.

2. The use according to claim 1, characterized in that: The liposome carrier also includes neutral liposomes, or a combination of neutral liposomes and cationic liposomes.

3. The use according to claim 1, characterized in that: The particle size of the cationic liposome is 100-300 nm.

4. The use according to claim 1, characterized in that: The product is a medicine or a reagent.

5. A pharmaceutical composition, characterized in that It includes: The composition according to any one of claims 1 to 4.

6. Use of the immune adjuvant according to any one of claims 1 to 4 in the preparation of a product for the treatment or adjuvant treatment of pancreatic cancer.